<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Drugs><Drug><Id>8713</Id><DrugType><Type>Small molecule therapeutic</Type></DrugType><DrugTargetMaturity><TargetIndication><IndicationId>3294</IndicationId><IndicationName>Metabolic syndrome X</IndicationName><MinPatentApplicationDate>2012-05-03T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-01526</TargetId><TargetName>PDE 5</TargetName></TargetIndication><TargetIndication><IndicationId>3660</IndicationId><IndicationName>Persistent pulmonary hypertension of the newborn</IndicationName><MinPatentApplicationDate>2018-01-09T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-01526</TargetId><TargetName>PDE 5</TargetName></TargetIndication><TargetIndication><IndicationId>1276</IndicationId><IndicationName>Female sexual dysfunction</IndicationName><MinPatentApplicationDate>1997-06-03T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-01526</TargetId><TargetName>PDE 5</TargetName></TargetIndication><TargetIndication><IndicationId>186</IndicationId><IndicationName>Erectile dysfunction</IndicationName><MinPatentApplicationDate>1993-06-09T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-01526</TargetId><TargetName>PDE 5</TargetName></TargetIndication><TargetIndication><IndicationId>3296</IndicationId><IndicationName>Diastolic heart failure</IndicationName><MinPatentApplicationDate>1999-02-04T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-01526</TargetId><TargetName>PDE 5</TargetName></TargetIndication><TargetIndication><IndicationId>3510</IndicationId><IndicationName>Pulmonary artery hypertension</IndicationName><MinPatentApplicationDate>1998-09-11T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-01526</TargetId><TargetName>PDE 5</TargetName></TargetIndication></DrugTargetMaturity><DevelopmentStatusCurrent><Row><Company id="18767">Pfizer Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1999-01-27T00:00:00Z</StatusDate><SourceLink type="PR" id="312051"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1999-01-27T00:00:00Z</StatusDate><SourceLink type="PR" id="312051"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1999-03-09T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="2082045"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>2001-03-27T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="402909"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1998-10-05T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1423629"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1999-01-19T00:00:00Z</StatusDate><SourceLink type="PR" id="312051"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1998-10-15T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1350430"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1999-01-27T00:00:00Z</StatusDate><SourceLink type="PR" id="312051"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1998-04-01T00:00:00Z</StatusDate><SourceLink type="PR" id="302381"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1999-03-23T00:00:00Z</StatusDate></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><SourceLink type="OTHER" id="1454583"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>2016-10-04T00:00:00Z</StatusDate><SourceLink type="OTHER" id="2125813"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="MA">Morocco</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>2018-11-13T00:00:00Z</StatusDate></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><SourceLink type="OTHER" id="1436218"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1998-10-01T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1389368"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>2018-08-08T00:00:00Z</StatusDate><SourceLink type="OTHER" id="2125821"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><SourceLink type="OTHER" id="1578126"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1999-01-27T00:00:00Z</StatusDate><SourceLink type="PR" id="312051"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1998-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="298479"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1999-12-31T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1514082"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1999-01-27T00:00:00Z</StatusDate><SourceLink type="PR" id="312051"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1998-04-30T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="1029806"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2006-06-12T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="2082015"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2005-10-28T00:00:00Z</StatusDate><SourceLink type="PR" id="664947"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2008-04-28T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="907839"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>1999-01-19T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1362932"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2015-04-01T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1716156"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2006-04-01T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="659012"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2005-10-20T00:00:00Z</StatusDate><SourceLink type="PR" id="629612"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3660">Persistent pulmonary hypertension of the newborn</Indication><StatusDate>2013-08-05T00:00:00Z</StatusDate><SourceLink type="TRIALREG" id="1446216"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3660">Persistent pulmonary hypertension of the newborn</Indication><StatusDate>2013-08-05T00:00:00Z</StatusDate><SourceLink type="TRIALREG" id="1446216"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3660">Persistent pulmonary hypertension of the newborn</Indication><StatusDate>2013-08-05T00:00:00Z</StatusDate><SourceLink type="TRIALREG" id="1446216"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2019-03-28T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="2135932"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="1276">Female sexual dysfunction</Indication><StatusDate>2004-02-27T00:00:00Z</StatusDate><SourceLink type="PR" id="525512"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="3296">Diastolic heart failure</Indication><StatusDate>2017-06-27T00:00:00Z</StatusDate></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="3296">Diastolic heart failure</Indication><StatusDate>2017-06-27T00:00:00Z</StatusDate></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="3294">Metabolic syndrome X</Indication><StatusDate>2016-10-31T00:00:00Z</StatusDate></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2013-01-01T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="1358082"/></Row></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Row><Company id="18767">Pfizer Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1998-06-01T00:00:00Z</StatusDate><SourceLink type="PR" id="289134"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1999-03-08T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="2082544"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1998-09-14T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1350430"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1998-12-31T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="1342232"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1999-01-26T00:00:00Z</StatusDate><SourceLink type="PR" id="312456"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>2004-04-19T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1456484"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1998-06-01T00:00:00Z</StatusDate><SourceLink type="PR" id="289134"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="MA">Morocco</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1998-06-01T00:00:00Z</StatusDate><SourceLink type="PR" id="289134"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1998-09-14T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1436217"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1998-06-01T00:00:00Z</StatusDate><SourceLink type="PR" id="289134"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1999-01-30T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1524000"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1998-03-27T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1484863"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2006-05-26T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="2082543"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2005-10-28T00:00:00Z</StatusDate><SourceLink type="PR" id="664947"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2008-01-25T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="896936"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2007-12-31T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="945381"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2005-12-15T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1362932"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2007-03-06T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1685979"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2005-06-06T00:00:00Z</StatusDate><SourceLink type="PR" id="605718"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1998-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="298479"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1998-08-06T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="293409"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><SourceLink type="SERIAL" id="207310"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2004-12-03T00:00:00Z</StatusDate><SourceLink type="PR" id="574429"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2007-11-22T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="859946"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2004-12-03T00:00:00Z</StatusDate><SourceLink type="PR" id="574429"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3296">Diastolic heart failure</Indication><StatusDate>2008-09-30T00:00:00Z</StatusDate><SourceLink type="TRIALREG" id="1391598"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3296">Diastolic heart failure</Indication><StatusDate>2008-09-30T00:00:00Z</StatusDate><SourceLink type="TRIALREG" id="1391598"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1996-01-01T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="197427"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2003-10-22T00:00:00Z</StatusDate><SourceLink type="PR" id="510165"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1276">Female sexual dysfunction</Indication><SourceLink type="SERIAL" id="294563"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3294">Metabolic syndrome X</Indication><StatusDate>2011-04-12T00:00:00Z</StatusDate><SourceLink type="TRIALREG" id="1650053"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortorder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="186">Erectile dysfunction</Indication><StatusDate>1996-04-18T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="204516"/></Row><Row><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2003-09-04T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="507877"/></Row></DevelopmentStatusHistoric></Drug></Drugs>